In silico antitarget screening

Maurizio Recanatini*, Giovanni Bottegoni, Andrea Cavalli

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

The need to early predict the possible failure of a drug candidate is becoming an absolute requirement in the drug discovery process. For this reason, from the initial phases of lead development, great attention is paid to the ADMET characteristics of the compounds. In this context, the recent discovery that hitting some well-identified macromolecular targets can induce undesired side effects has led drug designers to apply some classical in silico technologies to the goal of avoiding the interaction of lead candidates with such antitargets.

Original languageEnglish
Pages (from-to)209-215
Number of pages7
JournalDrug Discovery Today: Technologies
Volume1
Issue number3
DOIs
Publication statusPublished - 1 Dec 2004
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'In silico antitarget screening'. Together they form a unique fingerprint.

Cite this